This Week in Dermatology — Oct 16, 2026
Generated Oct 17, 2026 · 12:17
The week's practice-changing Dermatology research, summarized for clinicians.
If the audio fails to play, refresh the page to renew the link.
Get next week’s Dermatology briefing — free.
In your podcast app, or readable in your inbox with the audio one tap away.
Cancer Risk in Patients With Overall and Site-Specific Lichen Planus.
In nearly 36,000 Danish patients, lichen planus was linked to six- to sevenfold higher oral cancer rates and raised vulvar cancer rates, matching lesion site, though absolute risks stayed low.
JAMA Dermatology · 2026 · PubMed
This week’s papers
- 01
Cancer Risk in Patients With Overall and Site-Specific Lichen Planus.
In nearly 36,000 Danish patients, lichen planus was linked to six- to sevenfold higher oral cancer rates and raised vulvar cancer rates, matching lesion site, though absolute risks stayed low.
Medianfar CE et al. · JAMA Dermatology · 2026
From the briefingThe largest dataset this week comes from JAMA Dermatology, where Medianfar and colleagues used Danish nationwide registers to follow nearly 36,000 people with lichen planus, diagnosed between 1978 and 2020, for subsequent cancer [1]. Compared with the general population, women with lichen planus had roughly six to seven times the expected rate of cancers of the lip, oral cavity and tongue, and about two and a half times the expected rate of vulvar cancer. Skin squamous cell carcinoma was only modestly raised, and lung cancer was actually less common than expected. Men showed a similar pattern, and the risk held steady across follow-up. The most clinically useful finding is anatomical: oral lichen planus carried the highest oral cancer risk, and genital lichen planus the highest genital cancer risk. The absolute numbers keep this in proportion, with a twenty-year risk of oral cavity cancer of around one percent, and genital cancer well under half a percent. This is observational register data, so it cannot separate disease biology from treatment or detection effects, but the authors conclude that site-specific cancer should be regarded as a possible long-term complication of lichen planus.
If you only have time for one paper this week, make it the Danish lichen planus cancer cohort in JAMA Dermatology [1]. It gives the clearest population-level answer yet to a question raised in almost every lichen planus consultation, and its site-specific findings, with low absolute risks, frame the long-term surveillance discussion far more precisely than before.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 02
Female genital lichen sclerosus.
A review of female genital lichen sclerosus highlights its link with vulval neoplasia and squamous carcinoma, with ultrapotent topical steroids first-line and JAK inhibitors an emerging, little-tested option.
Spencer A, Gulin SJ · Journal of the European Academy of Dermatology and Venereology · 2026
From the briefingA narrative review in the Journal of the European Academy of Dermatology and Venereology by Spencer and Gulin on female genital lichen sclerosus reinforces the same principle in a neighbouring disease [2]. The authors describe the well-recognised link with differentiated vulval intraepithelial neoplasia and vulval squamous cell carcinoma, with chronic inflammation thought to drive carcinogenesis. They note that ultrapotent topical corticosteroids remain first-line therapy, alongside irritant avoidance, barrier protection and attention to urinary incontinence, and that JAK inhibitors may have a role in refractory disease, though trial data are still limited.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 03
Experience-based recommendations for the diagnosis and management of early-stage nail unit melanoma.
An international expert panel endorses matrix biopsy for diagnosis and wide excision with 6 to 10 millimetre margins for early nail unit melanoma, reserving amputation mainly for tumours over 1 millimetre.
Haneke E et al. · Journal of the European Academy of Dermatology and Venereology · 2026
From the briefingStaying with malignancy, an international expert panel led by Haneke, also in the Journal of the European Academy of Dermatology and Venereology, has published experience-based recommendations for early-stage nail unit melanoma, an area where the authors note no formal recommendations have existed [3]. Nail unit melanoma most often presents as a longitudinal pigmented band in an adult nail, and accounts for a small share of melanomas in white patients but up to half of melanomas in Black patients. The panel positions nail matrix biopsy with histopathology as the diagnostic gold standard, with dermoscopy as an aid. For in situ and early invasive disease they favour wide local excision with margins of 6 millimetres, extending to 10 millimetres when Hutchinson sign is present, reserving amputation largely for tumours thicker than 1 millimetre, and they propose ten years of follow-up. This is consensus rather than trial evidence, but it fills a real gap and supports a digit-sparing approach for early disease.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 04
Real-time assessment of mitotic rate in malignant melanoma by ex vivo confocal microscopy.
In a 40-melanoma pilot, ex vivo confocal microscopy correctly classified mitotic activity in 95 percent of tumours with no missed mitotically active cases, but requires larger multicentre validation.
Hartmann D et al. · Clinical and Experimental Dermatology · 2026
From the briefingOn the diagnostic technology side, Hartmann and colleagues in Clinical and Experimental Dermatology tested whether ex vivo confocal microscopy, which images fresh tissue within minutes, can assess melanoma mitotic rate, a marker that informs sentinel node decisions [4]. In 40 melanomas, the confocal method placed 95 percent of tumours correctly into the zero versus one-or-more mitoses groups, with no missed mitotically active tumours, though specificity was lower at just under eighty percent. This is a small pilot, and the authors are explicit that larger multicentre validation is needed before clinical use.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 05
Upadacitinib Combined with NB-UVB for Non-Segmental Vitiligo: A Single-Center Prospective Study.
In 38 adults with active refractory vitiligo, upadacitinib plus narrowband UVB achieved 50 percent improvement in about 47 percent versus 5 percent with phototherapy alone, without facial benefit.
Lu L et al. · Clinical and Experimental Dermatology · 2026
From the briefingIn Clinical and Experimental Dermatology, Lu and colleagues report a single-centre prospective study of adults with active, treatment-refractory non-segmental vitiligo, comparing oral upadacitinib 15 milligrams daily plus narrowband UVB against narrowband UVB alone for 12 weeks [5]. Just under half of patients on the combination reached at least fifty percent improvement in total vitiligo area score, compared with about one in twenty on phototherapy alone. The gains were concentrated on the trunk and non-acral limbs, while facial outcomes did not differ between groups, and adverse events were mild. With only 19 patients per arm, no randomisation and short follow-up, this is hypothesis-generating, as the authors acknowledge.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 06
Vitiligo Biomarker CXCL10 Correlates With Clinical Response to Ruxolitinib Cream in the Phase 2 Randomized TRuE-V Mechanism-of-Action Study.
Ruxolitinib cream lowered serum and skin CXCL10 in vitiligo, and these reductions correlated with repigmentation, supporting the interferon-gamma CXCL10 axis as a target and potential response biomarker.
Passeron T et al. · Journal of Investigative Dermatology · 2026
From the briefingThe mechanistic counterpart comes from the Journal of Investigative Dermatology, where Passeron and colleagues report the phase 2 randomised, vehicle-controlled TRuE-V mechanism-of-action study of 1.5 percent ruxolitinib cream [6]. Ruxolitinib cream reduced interferon-gamma related serum proteins, including the chemokine CXCL10, in both blood and lesional skin, and those reductions tracked with improvement in total vitiligo area scores. Facial scores fell by about half at 24 weeks, and increases in melanocyte counts correlated with facial repigmentation. Together these papers strengthen the case that the interferon-gamma and CXCL10 axis is a real treatment target, and they raise the possibility of CXCL10 as a response biomarker, though it is not yet validated for clinical monitoring. An interesting tension is the facial result: topical ruxolitinib worked best on the face, whereas the oral upadacitinib combination showed no facial advantage over phototherapy, a contrast that likely reflects the strong facial response to phototherapy alone and the small sample size.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 07
UVA1 Phototherapy in a national reference center:A 10-year systematical analysis.
Across 249 patients mainly with sclerosing dermatoses, atopic dermatitis or granuloma annulare, medium-dose UVA1 produced objective improvement in about 78 percent, mostly partial, with largely mild adverse events.
Vogel S et al. · Dermatology · 2026
From the briefingPhototherapy also features in a ten-year retrospective review from Zurich, published in Dermatology by Vogel and colleagues, covering 249 patients treated with predominantly medium-dose UVA1 [7]. The main indications were sclerosing dermatoses, atopic dermatitis and granuloma annulare. Just under four in five patients showed objective improvement, though most responses were partial, with only about one in seven complete. Response rates did not differ significantly between diagnostic groups, and about a quarter of patients had mild, transient erythema or hyperpigmentation, with one second-degree burn and no serious events. Without a comparator, this supports UVA1 as a reasonable option for selected sclerosing and inflammatory dermatoses rather than establishing its relative efficacy.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 08
LABD97 IgG ELISA increases sensitivity of ELISA serologic testing for the diagnosis of bullous pemphigoid.
An LABD97 IgG ELISA detected 87 percent of bullous pemphigoid sera versus 66 percent for the standard BP180 assay, including most patients negative on both commercial tests.
Snook JP et al. · Journal of the American Academy of Dermatology · 2026
From the briefingIn the Journal of the American Academy of Dermatology, Snook and colleagues address a familiar frustration in bullous pemphigoid: commercial antigen-specific serology misses roughly one in four patients who have circulating epidermal-pattern antibodies on indirect immunofluorescence [8]. In 100 consecutive suspected pemphigoid sera from the Utah immunodermatology laboratory, an ELISA targeting LABD97, a larger fragment of the BP180 ectodomain, detected 87 percent of cases, compared with about two thirds for the standard BP180 NC16A assay and about half for BP230. Among patients negative on both commercial tests, more than four in five were LABD97 positive. This is a single-centre study with limited clinical data, so it does not yet establish real-world performance, but it suggests a meaningful share of seronegative pemphigoid is a limitation of the antigen chosen rather than true seronegativity.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 09
Device-Free Auricular Acupressure for Rosacea: A Randomized Clinical Trial.
In a 204-patient sham-controlled trial, vagal-site auricular acupressure added to standard rosacea therapy raised clear or almost clear rates to 57 percent versus 35 percent, without serious adverse events.
Xu B et al. · JAMA Dermatology · 2026
From the briefingIn JAMA Dermatology, Xu and colleagues report a single-centre, sham-controlled randomised trial of device-free auricular acupressure in 204 patients with rosacea already on standard first-line therapy [9]. Patients pressed a seed taped over a vagally innervated area of the ear, or a sham site, three times daily for eight weeks. Treatment success, defined as clear or almost clear on investigator assessment, was reached by about 57 percent of the active group versus about 35 percent of the sham group, roughly one additional success for every five patients treated. Inflammatory and neuropeptide markers fell more in the active group, immediate vascular improvement was far more frequent, and benefit persisted at week 20 with no serious adverse events. Patients could not easily be blinded to which part of the ear they pressed, and this is a single centre in one country, so replication matters, but it is a cheap adjunct with a plausible neuroimmune rationale.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
- 10
Optimizing therapy in hidradenitis suppurativa: Combination, sequencing and treat-to-target.
A narrative review argues hidradenitis care should integrate biologics, time-limited antibiotics, metabolic therapy and surgery, prioritising early inflammatory control to prevent irreversible tunnels and disability.
Matusiak Ł et al. · Journal of the European Academy of Dermatology and Venereology · 2026
From the briefingFinally, a narrative review in the Journal of the European Academy of Dermatology and Venereology by Matusiak and colleagues, with Kirby among the authors, synthesises current thinking on hidradenitis suppurativa [10]. The authors argue for phenotype-driven integration of biologics, antibiotics, metabolic and hormonal therapies and surgery, framing antibiotics as time-limited induction rather than chronic suppression, and emphasising early inflammatory control within a possible window of opportunity before irreversible tunnels form. They also position pain and quality of life as treatment targets alongside lesion-based scores. This is expert opinion rather than new trial data, but it captures where hidradenitis management is heading.
Written by AI from the published abstract, for healthcare professionals. Not medical advice; check the paper before acting on it.
The full briefing
This AudioScholar briefing is generated by artificial intelligence for healthcare professionals and trainees. It is not medical advice.
Welcome to This Week in Dermatology. This week we're covering 10 notable papers spanning cancer risk in chronic inflammatory dermatoses and melanoma diagnostics, the expanding role of JAK inhibition and phototherapy in pigmentary and sclerosing disease, and fresh evidence on diagnosing and managing blistering, flushing and follicular inflammatory conditions. Let's dive in.
Our first theme is cancer vigilance, both in long-standing inflammatory disease and in melanoma at difficult sites. The largest dataset this week comes from JAMA Dermatology, where Medianfar and colleagues used Danish nationwide registers to follow nearly 36,000 people with lichen planus, diagnosed between 1978 and 2020, for subsequent cancer [1]. Compared with the general population, women with lichen planus had roughly six to seven times the expected rate of cancers of the lip, oral cavity and tongue, and about two and a half times the expected rate of vulvar cancer. Skin squamous cell carcinoma was only modestly raised, and lung cancer was actually less common than expected. Men showed a similar pattern, and the risk held steady across follow-up. The most clinically useful finding is anatomical: oral lichen planus carried the highest oral cancer risk, and genital lichen planus the highest genital cancer risk. The absolute numbers keep this in proportion, with a twenty-year risk of oral cavity cancer of around one percent, and genital cancer well under half a percent. This is observational register data, so it cannot separate disease biology from treatment or detection effects, but the authors conclude that site-specific cancer should be regarded as a possible long-term complication of lichen planus. A narrative review in the Journal of the European Academy of Dermatology and Venereology by Spencer and Gulin on female genital lichen sclerosus reinforces the same principle in a neighbouring disease [2]. The authors describe the well-recognised link with differentiated vulval intraepithelial neoplasia and vulval squamous cell carcinoma, with chronic inflammation thought to drive carcinogenesis. They note that ultrapotent topical corticosteroids remain first-line therapy, alongside irritant avoidance, barrier protection and attention to urinary incontinence, and that JAK inhibitors may have a role in refractory disease, though trial data are still limited.
Staying with malignancy, an international expert panel led by Haneke, also in the Journal of the European Academy of Dermatology and Venereology, has published experience-based recommendations for early-stage nail unit melanoma, an area where the authors note no formal recommendations have existed [3]. Nail unit melanoma most often presents as a longitudinal pigmented band in an adult nail, and accounts for a small share of melanomas in white patients but up to half of melanomas in Black patients. The panel positions nail matrix biopsy with histopathology as the diagnostic gold standard, with dermoscopy as an aid. For in situ and early invasive disease they favour wide local excision with margins of 6 millimetres, extending to 10 millimetres when Hutchinson sign is present, reserving amputation largely for tumours thicker than 1 millimetre, and they propose ten years of follow-up. This is consensus rather than trial evidence, but it fills a real gap and supports a digit-sparing approach for early disease. On the diagnostic technology side, Hartmann and colleagues in Clinical and Experimental Dermatology tested whether ex vivo confocal microscopy, which images fresh tissue within minutes, can assess melanoma mitotic rate, a marker that informs sentinel node decisions [4]. In 40 melanomas, the confocal method placed 95 percent of tumours correctly into the zero versus one-or-more mitoses groups, with no missed mitotically active tumours, though specificity was lower at just under eighty percent. This is a small pilot, and the authors are explicit that larger multicentre validation is needed before clinical use.
Our second theme is repigmentation and phototherapy, where JAK inhibition is moving from proof of concept toward combination strategies and mechanistic understanding. In Clinical and Experimental Dermatology, Lu and colleagues report a single-centre prospective study of adults with active, treatment-refractory non-segmental vitiligo, comparing oral upadacitinib 15 milligrams daily plus narrowband UVB against narrowband UVB alone for 12 weeks [5]. Just under half of patients on the combination reached at least fifty percent improvement in total vitiligo area score, compared with about one in twenty on phototherapy alone. The gains were concentrated on the trunk and non-acral limbs, while facial outcomes did not differ between groups, and adverse events were mild. With only 19 patients per arm, no randomisation and short follow-up, this is hypothesis-generating, as the authors acknowledge. The mechanistic counterpart comes from the Journal of Investigative Dermatology, where Passeron and colleagues report the phase 2 randomised, vehicle-controlled TRuE-V mechanism-of-action study of 1.5 percent ruxolitinib cream [6]. Ruxolitinib cream reduced interferon-gamma related serum proteins, including the chemokine CXCL10, in both blood and lesional skin, and those reductions tracked with improvement in total vitiligo area scores. Facial scores fell by about half at 24 weeks, and increases in melanocyte counts correlated with facial repigmentation. Together these papers strengthen the case that the interferon-gamma and CXCL10 axis is a real treatment target, and they raise the possibility of CXCL10 as a response biomarker, though it is not yet validated for clinical monitoring. An interesting tension is the facial result: topical ruxolitinib worked best on the face, whereas the oral upadacitinib combination showed no facial advantage over phototherapy, a contrast that likely reflects the strong facial response to phototherapy alone and the small sample size.
Phototherapy also features in a ten-year retrospective review from Zurich, published in Dermatology by Vogel and colleagues, covering 249 patients treated with predominantly medium-dose UVA1 [7]. The main indications were sclerosing dermatoses, atopic dermatitis and granuloma annulare. Just under four in five patients showed objective improvement, though most responses were partial, with only about one in seven complete. Response rates did not differ significantly between diagnostic groups, and about a quarter of patients had mild, transient erythema or hyperpigmentation, with one second-degree burn and no serious events. Without a comparator, this supports UVA1 as a reasonable option for selected sclerosing and inflammatory dermatoses rather than establishing its relative efficacy.
Our third theme covers diagnosis and treatment strategy in inflammatory and autoimmune skin disease. In the Journal of the American Academy of Dermatology, Snook and colleagues address a familiar frustration in bullous pemphigoid: commercial antigen-specific serology misses roughly one in four patients who have circulating epidermal-pattern antibodies on indirect immunofluorescence [8]. In 100 consecutive suspected pemphigoid sera from the Utah immunodermatology laboratory, an ELISA targeting LABD97, a larger fragment of the BP180 ectodomain, detected 87 percent of cases, compared with about two thirds for the standard BP180 NC16A assay and about half for BP230. Among patients negative on both commercial tests, more than four in five were LABD97 positive. This is a single-centre study with limited clinical data, so it does not yet establish real-world performance, but it suggests a meaningful share of seronegative pemphigoid is a limitation of the antigen chosen rather than true seronegativity. In JAMA Dermatology, Xu and colleagues report a single-centre, sham-controlled randomised trial of device-free auricular acupressure in 204 patients with rosacea already on standard first-line therapy [9]. Patients pressed a seed taped over a vagally innervated area of the ear, or a sham site, three times daily for eight weeks. Treatment success, defined as clear or almost clear on investigator assessment, was reached by about 57 percent of the active group versus about 35 percent of the sham group, roughly one additional success for every five patients treated. Inflammatory and neuropeptide markers fell more in the active group, immediate vascular improvement was far more frequent, and benefit persisted at week 20 with no serious adverse events. Patients could not easily be blinded to which part of the ear they pressed, and this is a single centre in one country, so replication matters, but it is a cheap adjunct with a plausible neuroimmune rationale. Finally, a narrative review in the Journal of the European Academy of Dermatology and Venereology by Matusiak and colleagues, with Kirby among the authors, synthesises current thinking on hidradenitis suppurativa [10]. The authors argue for phenotype-driven integration of biologics, antibiotics, metabolic and hormonal therapies and surgery, framing antibiotics as time-limited induction rather than chronic suppression, and emphasising early inflammatory control within a possible window of opportunity before irreversible tunnels form. They also position pain and quality of life as treatment targets alongside lesion-based scores. This is expert opinion rather than new trial data, but it captures where hidradenitis management is heading.
If you only have time for one paper this week, make it the Danish lichen planus cancer cohort in JAMA Dermatology [1]. It gives the clearest population-level answer yet to a question raised in almost every lichen planus consultation, and its site-specific findings, with low absolute risks, frame the long-term surveillance discussion far more precisely than before.
Here is what this week's evidence adds up to in Dermatology. First, large register data now show that oral and genital lichen planus carry markedly raised relative risks of cancer at the same site, with low absolute risk, and a review of genital lichen sclerosus reaffirms a similar inflammation-to-malignancy link; how surveillance should be structured remains unsettled. Second, early nail unit melanoma now has expert consensus supporting margin-based, digit-sparing excision, though this rests on experience rather than comparative trials. Third, JAK inhibition in vitiligo is gaining both mechanistic support, through CXCL10 reduction with ruxolitinib cream, and early combination data with oral upadacitinib and phototherapy, but the combination evidence is small, non-randomised and short. Fourth, an expanded LABD97 ELISA appears to capture many pemphigoid patients missed by commercial serology, pending multicentre validation. And fifth, a single-centre sham-controlled trial suggests auricular acupressure adds benefit to standard rosacea care, a finding that needs independent replication.
That's your roundup for This Week in Dermatology. The full transcript and references are available on the episode page. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.
If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And a quick rating on Apple Podcasts or Spotify helps other physicians discover the show.
This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.
Spot something worth flagging?
Get this every week in your podcast app — free.
New dermatology episodes land in your feed automatically — listen on your commute.